CytRx Corporation announced that its Board of Directors has approved the appointment of Eric L. Curtis, MBA, to the company's executive management team, as President and Chief Operating Officer, effective May 3, 2018. Mr. Curtis brings 25 years of life science leadership experience to CytRx, with a proven track record in oncology and orphan diseases, including the development and commercialization of several approved and marketed cancer drugs such as Votrient®, Doxil®, Velcade®, Benlysta® and Tykerb®. Most recently, he has provided strategic consultancy services to a variety of healthcare-focused companies, including CytRx. Before joining CytRx, Mr. Curtis served as President, U.S. Commercial at Aegerion Pharmaceuticals (now Novelion Therapeutics), where he was instrumental in designing and implementing the division's structure and business strategy. Prior to Aegerion, Mr. Curtis served as Vice President and General Manager Rare Disease/Cardiopulmonary Business Unit at Bayer Healthcare, where he successfully led the design and build of this new US commercial business unit.